Supplemental Patient Surveillance System, in Conjunction with Masimo
SET® and rainbow®
Monitors, Provides Continuous Remote Monitoring 24 Hours a Day
GURGAON, India--(BUSINESS WIRE)--Dec. 1, 2017--
Masimo (NASDAQ:
MASI) announced today that Artemis Hospital, one of the leading
multi-specialty hospitals in the Delhi-NCR region of India, is adopting
Masimo Patient SafetyNet™*, a supplemental remote monitoring and
clinician notification system, across all hospital care areas.
Patient SafetyNet, in conjunction with SET® pulse oximetry
and rainbow® pulse CO-oximetry, will enable the hospital team
to monitor key patient parameters and gain insight, via changes in
patient status recorded by Masimo bedside monitors, into possible signs
of patient deterioration. Artemis is the first hospital in India to
offer such round-the-clock patient surveillance across all specialties.
With Patient SafetyNet, Artemis hopes to achieve results similar to
those achieved at Dartmouth-Hitchcock Medical Center in the United
States: In 2016, the Medical Center, which had been using Masimo SET®
pulse oximetry and Patient SafetyNet as part of a comprehensive
alarm management strategy in all medical-surgical units for ten years,
reported achieving a 50% reduction in unplanned ICU transfers and a 60%
reduction in rescue events over those ten years, despite increases in
patient acuity and occupancy.1,2
“Artemis is renowned for its patient-centric care and we wanted to
further augment it using technologies that can continuously monitor
patients across different care areas,” said Dr. Devlina Chakravarty,
Executive Director of Artemis Hospitals. “Given our stringent standards
for quality and state-of-the-art infrastructure, Patient SafetyNet was a
natural fit.”
Patient SafetyNet allows clinicians at a central station to review
patient data continuously relayed from bedside monitoring devices. It
also features a robust supplemental alarm notification and escalation
process that relays notifications to clinicians wherever they may be in
the hospital. If notifications remain unacknowledged, they are escalated
to additional clinicians per a customizable protocol.
Dr. (Col.) Manjinder Singh Sandhu, Medical Director and
Director-Cardiology, Artemis Hospitals, said, “Artemis has always been
ahead of the industry in adopting initiatives and technologies that can
improve patient care. Continuous supplemental remote monitoring in areas
not usually monitored is one such initiative and we wanted a solution
that can seamlessly integrate with our existing protocols and
infrastructure. We found Masimo Patient SafetyNet to be one such system
that offered both unmatched value and hassle-free integration.”
Jon Coleman, President of Worldwide Sales, Professional Services, and
Medical Affairs, Masimo, said, “Artemis is leading the way for patient
safety in India with their commitment to monitor all of their patients
all of the time. Continuous remote monitoring with SET®
technology saves lives and precious resources. We are delighted to serve
Artemis Hospital with our technology.”
Bharat Monteiro, Country Manager, India and ISC, for Masimo, added, “We
are in the process of altering the landscape of continuous and remote
monitoring in India with our customized product offerings and unique
value proposition. Masimo and Artemis share a commitment to patient care
and we are excited to work with the Artemis team to help make a
difference in care and satisfaction of their patients and clinicians.”
Artemis care areas will be equipped with bedside monitoring devices such
as the Radius-7® Pulse CO-Oximeter®, a Bluetooth-
and WiFi-enabled wearable, tetherless monitor used in conjunction with
the Root® Patient Monitoring and Connectivity Platform, as
well as Rad-97™, Masimo’s most recent bedside pulse CO-oximeter. These
devices feature SET® Measure-through Motion and Low
Perfusion™ pulse oximetry technology to measure oxygen saturation, pulse
rate, and perfusion index for all patients, with fewer of the false
alarms3 that have made monitoring patients in less
nurse-intensive areas impractical. A subset of patients will also be
monitored using SpHb®, a Masimo rainbow® parameter
that measures hemoglobin, continuously and noninvasively. Each floor
will also use a cart-mounted Root with Noninvasive Integrated Blood
Pressure and Temperature monitor to provide periodic spot-checking of
vital signs and input for automated Early Warning Scores, built into
Root. Patient data from all of these devices, in addition to being
relayed to Patient SafetyNet, will be automatically integrated with the
hospital’s electronic medical record (EMR) and hospital information
system (HIS).
Artemis Hospital, established in 2007, is a 380-bed, state-of-the-art
multi-specialty hospital located in Gurgaon, India, the first in Gurgaon
to be accredited by the Joint Commission International (JCI) and the
National Accreditation Board for Hospitals and Healthcare Providers
(NABH).
@MasimoInnovates |
#Masimo
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
References
-
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
-
Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience.
Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
-
Shah N et al. Performance of Three New-Generation Pulse Oximeters
during Motion and Low Perfusion in Volunteers. J Clin Anesth.
2012 Aug;24(5):385-91.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™*
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 and is the primary pulse oximetry at 17 of the top 20
hospitals listed in the 2017-18 U.S. News and World Report Best
Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect™ (MOC-9™) interface, enabling other companies to
augment Root with new features and measurement capabilities. Masimo is
also taking an active leadership role in mHealth with products such as
the Radius-7™ wearable patient monitor, iSpO2®
pulse oximeter for smartphones, and the MightySat™ fingertip pulse
oximeter. Additional information about Masimo and its products may be
found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
ORi has not received FDA 510(k) clearance and is not available for sale
in the United States.
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
References
-
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
-
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;338.
-
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
Events and Intensive Care Unit Transfers: A Before-And-After
Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
-
Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
-
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
-
Estimate: Masimo data on file.
- http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo Patient SafetyNet™. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo Patient SafetyNet, contribute to positive
clinical outcomes and patient safety; risks related to our belief that
Masimo noninvasive medical breakthroughs provide cost-effective
solutions and unique advantages; as well as other factors discussed in
the "Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171130006328/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com